• Lexicon Pharmaceuticals Inc., of The Woodlands, Texas, said top-line data from an initial Phase II study exploring the use of LX1033 in diarrhea-predominant irritable bowel syndrome (IBS-d) indicated that all treatment groups, including placebo, showed significant improvements over time, and differences between placebo and LX1033 in stool consistency – the study’s primary endpoint – were not statistically significant.